PTR cell variants representing acquired resistance were generated using in vivo tumor models that were initially sensitive to anti-PD-L1 (αPD-L1) treatment and thus able to better mimic the complex tumor:immune cell interactions that occur during the progression to treatment failure. This evidence concerns the gene CD274 and neoplasm.